EMA might de­ny Mer­ck­'s mol­nupi­ravir con­di­tion­al mar­ket­ing au­tho­riza­tion — re­port

While Mer­ck’s Covid-19 an­tivi­ral mol­nupi­ravir has been giv­en EUA in the US, it has still been pend­ing au­tho­riza­tion in Eu­rope. And ac­cord­ing to a new re­port from the Fi­nan­cial Times, the EMA might not rec­om­mend grant­i­ng con­di­tion­al mar­ket­ing au­tho­riza­tion — po­ten­tial­ly shut­ting Mer­ck’s an­tivi­ral out of one of the world’s largest drug mar­kets.

Peo­ple fa­mil­iar with the ap­proval process told the news or­ga­ni­za­tion that the EMA is un­like­ly to grant con­di­tion­al mar­ket­ing au­tho­riza­tion to Mer­ck’s Covid-19 an­tivi­ral as it wres­tles with “prob­lem­at­ic” da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER